Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: FEBS Lett. 2018 Sep 20;592(19):3274–3285. doi: 10.1002/1873-3468.13236

Figure 5. FNH nanoparticles and GFP-CD63 exosomes move to the perinuclear compartments of the cell and attenuate both motility and invasion of prostate cancer tumor cells.

Figure 5.

In A’, GFP-CD63 exosomes (4 μg/chamber) and rhodamine labeled FNH nanoparticles (4 μg/chamber) were added to DU145 prostate cancer cells in 8-chambered glass slides. The green channel, panels A and C represent uptake of GFP-CD63 exosomes while the merged panels B and D show both GFP-CD63 exosomes and FNH nanoparticles which indicates that some of the exosomes were co-localized with FNH nanoparticles (arrows). In B’, the motility (panel A) and invasion (panel B) assays were done using Boyden Chambers as described. Briefly, the cells (DU145) were added to the upper chambers in SFM without (control) or with nanoparticles FN or FNH (100 μg/chamber). The lower chambers contained 500 μl of complete medium (10% fetal bovine serum). * P < 0.05, N = 6; one way ANOVA.